Carlsbad, California, October 30, 2013 /Marketwired/ - Aurora Spine Corporation (TSXV: ASG), a global minimally invasive (MIS) spinal implant company, is pleased to announce the first US surgical usage of the company's AmnioPUR(TM) liquid allograft products in a lumbar spinal procedure. AmnioPUR was introduced in mid-October at EuroSpine congress in Liverpool, England and again at the North American Spine Society (NASS) in New Orleans, LA. AmnioPUR is a multipurpose, chorion free, cryopreserved allograft, AmnioPUR is derived from the amniotic membrane.
"Aurora Biologics, specifically our AmnioPUR product is another key step in bringing the best products to our worldwide distribution network. The clinical benefit of amnion is well documented, we just made it easier to use by providing AmnioPUR in a liquid form" said Brent W. Johnston, CCO of Aurora Spine.
AmnioPUR(TM) provides an anti-microbial environment with anti-inflammatory characteristics and anti-adhesion/anti-fibrotic capabilities and provides a structural matrix for use in filling bone voids and soft tissue.
"The launch of AmnioPUR is a major milestone for Aurora Spine, as we now offer surgeons a comprehensive liquid allograft solution from a provider they trust," said Trent J. Northcutt, President and CEO of Aurora Spine. "Surgeons know Aurora provides modern technologies for today's patients ailing from spinal complications. Aurora is committed to the development, distribution and licensing arrangements of advanced biologics and tissue allografts, which make up one of the fastest growing segments in the global spine market."
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the growth potential of Aurora Spine's products. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
For more information, please contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Kenneth Gross
Chief Financial Officer
(760) 424-2004
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Aurora Spine Corporation via Thomson Reuters ONE
